WATERTOWN, Mass. , Oct. 08, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced an amendment to its existing debt facility with CRG Servicing LLC (CRG).

- Q 3 20 20 net product revenues are estimated to be between $ 5.5   - $ 5.9   million, as   healthcare facilities began reopening from COVID-19 closures - - Sequential increase in underlying customer demand for both YUTIQ and DEXYCU from Q2 2020 WATERTOWN, Mass. , Oct.

WATERTOWN, Mass. , Sept. 10, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Nancy Lurker , President and Chief Executive Officer, will present in two

WATERTOWN, Mass. , Aug. 24, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it has entered into a purchase and marketing agreement with Vantage

WATERTOWN, Mass. , Aug. 20, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, and Ocumension Therapeutics, a China -based ophthalmic pharmaceutical platform company, today

- Total revenues of $4.1 million and net product revenues of $3.7 million impacted by COVID-19 pandemic - - U.S. commercial alliance with ImprimisRx to expand reach of DEXYCU® - - Jay S. Duker , M.D., world-renowned retinal specialist, joins as Chief Strategic Scientific Officer to lead EYP-1901

- Collaboration to bring DEXYCU to ImprimisRx’s established customer base of ophthalmologists, hospitals, and ambulatory surgical centers - WATERTOWN, Mass. and NASHVILLE, Tenn. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to

WATERTOWN, Mass. , July 29, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its second quarter 2020 on Wednesday, August 5, 2020 .

WATERTOWN, Mass. , July 27, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the presentation of data supporting YUTIQ® (fluocinolone acetonide intravitreal

- World-renowned retina specialist to lead EYP-1901 development efforts and support expansion of EyePoint’s ocular disease pipeline - WATERTOWN, Mass. , July 13, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and

WATERTOWN, Mass. , May 26, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Nancy Lurker , President and Chief Executive Officer, is scheduled to present

WATERTOWN, Mass. , May 18, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the presentation of positive retrospective case study data supporting DEXYCU®

- Total revenues of $7.5 million and net product revenues of $4.7 million - - Cash conservation and reorganization initiatives coupled with recent financings support cash runway into 2021 under current COVID-19 pandemic assumptions - - GLP toxicology studies initiated for EYP-1901, a six-month

WATERTOWN, Mass. , April 29, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its first quarter 2020 on Wednesday, May 6, 2020 .

- Proactive Efforts to Mitigate Spread and Protect Safety and Well-being of Patients, Treating Physicians, Employees and Our Communities - - Reorganization of Commercial Operations to Align with Focused Approach - WATERTOWN, Mass. , April 01, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals ,

– Total revenues of $8.6 million in Q4  2019 and $20.4 million for full year 2019 – –  Net product revenues of $7.9 million in Q4 2019 and $16.8 million for full year 2019 – – Q4 2019 customer demand for DEXYCU and YUTIQ Increased 111% and 59%, respectively, compared to Q3 2019 – – EYP-1901, a

36-month data showed uveitis eye flare recurrence rate of 46.5% in YUTIQ-treated eyes vs. 75.0% in sham eyes, a 40% reduction WATERTOWN, Mass. , March 02, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing

WATERTOWN, Mass. , Feb. 27, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its fourth quarter and full-year ended December 31, 2019 on Thursday,

WATERTOWN, Mass. , Feb. 21, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products today announced the pricing of an underwritten public offering of 15,000,000 shares of its

WATERTOWN, Mass. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it intends to offer and sell shares of its common stock in an